Opinion
Video
Current FCS Standard-of-Care Treatment Recommendations
Author(s):
Key Takeaways
- Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
- Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Panelists discuss the current standard-of-care treatment recommendations for familial chylomicronemia syndrome (FCS) from an endocrinologist’s perspective, addressing the use of fibrates, omega-3 fatty acids, and statins despite their lack of approval for FCS; their typical impact on triglyceride reduction; the reasons these therapies are often ineffective in FCS; the gaps in existing treatments; and the associated risks of acute pancreatitis and hospitalization, along with potential adverse effects of these therapies.
Video content above is prompted by the following:
- As an endocrinologist, what are your perspectives on current standard-of-care treatment recommendations for FCS, given there are currently no approved treatments for FCS (eg, fibrates, omega-3 fatty acids, statins)?
- What is the typical reduction in triglycerides from using these treatments?
- Why are standard lipid-lowering therapies typically ineffective for patients with FCS?
- What are the gaps in existing treatments for FCS in terms of reducing triglyceride levels, and how do these gaps contribute to the risk of acute pancreatitis and the need for hospitalization?
- What are the potential adverse effects associated with the FCS therapies we just reviewed?
Related Videos
Related Content
